Oruka Therapeutics (NASDAQ:ORKA) SVP Sells $872,403.57 in Stock

Oruka Therapeutics, Inc. (NASDAQ:ORKA) SVP Arjun Agarwal sold 9,459 shares of the firm’s stock in a transaction dated Friday, September 11th. The shares were sold at an average price of $92.23, for a total transaction of $872,403.57. Following the completion of the sale, the senior vice president owned 15,312 shares of the company’s stock, valued at $1,412,225.76. This trade represents a 38.19% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

Arjun Agarwal also recently made the following trade(s):

• On Tuesday, September 15th, Arjun Agarwal sold 560 shares of Oruka Therapeutics stock. The stock was sold at an average price of $95.71, for a total value of $53,597.60.
• On Thursday, August 13th, Arjun Agarwal sold 10,000 shares of Oruka Therapeutics stock. The stock was sold at an average price of $106.66, for a total value of $1,066,600.00.
• On Monday, July 13th, Arjun Agarwal sold 9,999 shares of Oruka Therapeutics stock. The shares were sold at an average price of $84.63, for a total value of $846,215.37.
• On Monday, June 22nd, Arjun Agarwal sold 1,587 shares of Oruka Therapeutics stock. The shares were sold at an average price of $80.95, for a total value of $128,467.65.

Oruka Therapeutics Trading Up 4.5%

Shares of NASDAQ ORKA opened at $97.73 on Friday. Oruka Therapeutics, Inc. has a 12 month low of $14.89 and a 12 month high of $115.51. The stock has a 50 day moving average of $96.24 and a 200-day moving average of $73.64. The company has a market capitalization of $6.47 billion, a P/E ratio of -48.14 and a beta of -0.34.

Oruka Therapeutics (NASDAQ:ORKA) last posted its earnings results on Monday, August 10th. The company reported ($0.55) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.51) by ($0.04). Analysts predict that Oruka Therapeutics, Inc. will post -2.42 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

Several brokerages have recently weighed in on ORKA. BTIG Research reissued a “buy” rating and issued a $151.00 price objective on shares of Oruka Therapeutics in a research report on Tuesday, August 11th. Weiss Ratings upgraded shares of Oruka Therapeutics from a “sell (e+)” rating to a “sell (d-)” rating in a research note on Wednesday, July 15th. Wall Street Zen cut shares of Oruka Therapeutics from a “hold” rating to a “sell” rating in a report on Sunday, August 16th. Mizuho set a $120.00 price objective on shares of Oruka Therapeutics in a research report on Thursday, September 3rd. Finally, UBS Group boosted their price objective on Oruka Therapeutics from $100.00 to $130.00 and gave the stock a “buy” rating in a report on Wednesday, July 1st. Ten analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company. According to data from MarketBeat.com, Oruka Therapeutics has an average rating of “Moderate Buy” and an average price target of $133.00.

Institutional Investors Weigh In On Oruka Therapeutics

A number of hedge funds and other institutional investors have recently modified their holdings of ORKA. Engineers Gate Manager LP bought a new stake in shares of Oruka Therapeutics in the second quarter valued at about $350,000. Arizona State Retirement System increased its position in Oruka Therapeutics by 45.0% during the second quarter. Arizona State Retirement System now owns 8,671 shares of the company’s stock worth $825,000 after acquiring an additional 2,691 shares during the period. Nykredit A S bought a new position in Oruka Therapeutics during the second quarter worth about $29,000. Braidwell LP acquired a new stake in Oruka Therapeutics in the 2nd quarter worth about $26,473,000. Finally, Natural Investments LLC acquired a new stake in Oruka Therapeutics in the 2nd quarter worth about $202,000. Institutional investors and hedge funds own 56.44% of the company’s stock.

Oruka Therapeutics Company Profile

Oruka Therapeutics, Inc (NASDAQ:ORKA) is a clinical-stage biotechnology company developing long-acting monoclonal antibody therapies for immune-mediated diseases. The company’s research is focused on creating medicines that may allow less frequent dosing than existing biologic treatments.

Oruka’s initial development programs are aimed at inflammatory conditions, including psoriasis. Its pipeline includes engineered antibody candidates designed to target important immune pathways, including interleukin-23 and interleukin-17.